Everything About Corbevax - India's First RBD Protein Covid Vaccine for 12-14 Year Children
"I am happy to inform that from March 16, COVID vaccination of children in the age group of 12 to 13 and 13 to 14 is starting."
On Monday, Mansukh Mandaviya, the Union Health Minister, announced that vaccines for children between 12 and 14 years of age will begin on March 16. The precautionary dose is now available to anyone over the age of 60. Before, only those with comorbidities were given this dose.
Mansukh Mandaviya, the Union Health Minister, encouraged those aged 60 and above and families of children to take the respective dose of vaccine. Corbevax Covid-19 vaccine, manufactured by Hyderabad-based Biological E Ltd., is to be given to children aged 12 to 14 years.
Guideline for Corbevax Vaccine in India
A new set of guidelines for the COVID-19 vaccination was released today by the Ministry of Health and Family Welfare. The official release mentions that the beneficiaries in the 12-14 age group will be offered two doses of Biological E's intramuscular vaccine Corbevax at a 28-day interval.
Children between 12-14 years old will begin receiving COVID-19 vaccinations on March 16, and only the Corbevax vaccine will be administered to beneficiaries between 12-13 and 13-14 years, according to the statement. Vaccination for the 15–18-year-old age group already included beneficiaries between the ages of 14-15 years.
A precautionary dose has been approved for all persons 60 years and older. This dose should be given 9 months or 39 weeks after the second dose.
A new set of guidelines for the COVID-19 vaccination was released today by the Ministry of Health and Family Welfare. The official release mentions that the beneficiaries in the 12-14 age group will be offered two doses of Biological E's intramuscular vaccine Corbevax at a 28-day interval.
Children between 12-14 years old will begin receiving COVID-19 vaccinations on March 16, and only the Corbevax vaccine will be administered to beneficiaries between 12-13 and 13-14 years, according to the statement. Vaccination for the 15–18-year-old age group already included beneficiaries between the ages of 14-15 years.
A precautionary dose has been approved for all persons 60 years and older. This dose should be given 9 months or 39 weeks after the second dose.
How to Register for Corbevax Vaccine:
According to guidelines, self-registration can be done with a family member's existing account on Co-WIN or a new account can be created through a unique mobile number. You can also register onsite with the vaccinator in facilitated registration mode, and appointments for 12-14 years can be scheduled either online or onsite (walk-in).
The government has already taken steps to ensure that people in the country over the age of 14 are vaccinated against Covid-19 as part of the ongoing vaccination campaign. The vaccination program in India began on 3 January 2022 for 15–18-year-olds.
Bharat Biotech's Covaxin shots were administered to children until now. A recent report stated that Biological E. Limited applied for Emergency Use Authorization (EUA) for Corbevax, its candidate for Covid-19 for children ages 5-12.
According to guidelines, self-registration can be done with a family member's existing account on Co-WIN or a new account can be created through a unique mobile number. You can also register onsite with the vaccinator in facilitated registration mode, and appointments for 12-14 years can be scheduled either online or onsite (walk-in).
The government has already taken steps to ensure that people in the country over the age of 14 are vaccinated against Covid-19 as part of the ongoing vaccination campaign. The vaccination program in India began on 3 January 2022 for 15–18-year-olds.
Bharat Biotech's Covaxin shots were administered to children until now. A recent report stated that Biological E. Limited applied for Emergency Use Authorization (EUA) for Corbevax, its candidate for Covid-19 for children ages 5-12.
About Corbevax
- Dynavax Technologies of Emeryville, California, in conjunction with Texas Children's Hospital Center for Vaccine Development and Baylor College of Medicine in Houston, Texas, have developed Corbevax, a protein-subunit vaccine against COVID-19. A license has been granted to Indian biopharmaceutical company Biological E. Limited (BioE) to develop and produce this vaccine.
- An adjuvant consisting of aluminum hydroxide gel and CpG 1018 is added to the receptor-binding domain (RBD) of the SARSCoV2 spike protein as part of the vaccine. This protein is made by a yeast known as Pichia pastoris, and is produced in a similar manner to current Hepatitis B vaccines.
- It is also possible that Corbevax is India's most affordable vaccine. Two doses of the vaccine are expected to cost under Rs 400. Vaccines such as Covishield and the Russian vaccine Sputnik V cost around Rs 300-400 and Rs 1,000, Rs 300-400 and Rs 1,000, respectively. For two doses of Covaxin, the cost is approximately Rs 1,400.
- In April 2021, the United States International Development Finance Corporation (DFC) stated that they would fund BioE's (Biological E Ltd, India) manufacturing capacity so that the company could manufacture 1 billion doses by the end of 2022.
- Corbevax will be administered to children 12-14 years old. Corbevax was approved for limited use in adults on December 28, 2021, by the Drug Controller General of India (DGCI).
- The Indian drug regulator granted Corbevax emergency use authorization (EUA) for 12-18-year-olds in February this year. Corbevax is the first vaccine in the country built on RBD protein sub-units to counter the virus.
- The expert committee of India's Central Drugs Authority recommended on February 14 that children aged 12 to 18 years with certain conditions be given the Covid-19 vaccine Corbevax by Biological E.
- The Indian Drugs Controller General (DCGI) on February 21 approved Corbevax, an anti-Covid-19 vaccine developed by Biological E, for limited emergency use (EUA) by children ages 12 to 18.
- Against the variant found in Wuhan, China, the Corbevax vaccine was more than 90% effective while its effectiveness against the Delta variant was more than 80%. The effectiveness of the drug against Omicron variants is being assessed, according to reports.
- For the age group of 12 to 18 years, Corbevax is the third vaccine approved by DCGI. Before Corbevax DCGI had approved Covaxin of Bharat Biotech and Zycov-D of Zydus Cadila were approved.
- Developers of the Corbevax Covid-19 vaccine decided not to apply for any patents on the technology of the vaccine, as this will allow it to be replicated all over the world. In order to protect as many people from contracting severe diseases, the makers want the vaccination to be available to as many people as possible.
Comments